Synthesis and biological evaluation of novel 99mtc-labelled bisphosphonates as superior bone imaging agents

Molecules

Volumn 16, Issue 8, 2011, Pages 6165-6178

  Qiu, Ling ^a   Cheng, Wen ^a   Lin, Jianguo ^a   Luo, Shineng ^a   Xue, Li ^a   Pan, Jing ^a  

^a BEIJING HOSPITAL   (China)

Author keywords

99mTc labelled diphosphonates; Biodistribution; Bone imaging agent; In vitro stability; Zoledronic acid derivative

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; IMIDAZOLE DERIVATIVE; PLASMA PROTEIN; RADIOPHARMACEUTICAL AGENT; TECHNETIUM; TECHNETIUM COMPLEX;

ANIMAL; ARTICLE; BONE; CHEMICAL PHENOMENA; CHEMISTRY; DRUG STABILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; METHODOLOGY; MOLECULAR IMAGING; MOUSE; PROTEIN BINDING; SCINTISCANNING; SYNTHESIS; TISSUE DISTRIBUTION;

ANIMALS; BLOOD PROTEINS; BONE AND BONES; BONE DENSITY CONSERVATION AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIPHOSPHONATES; DRUG STABILITY; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; IMIDAZOLES; INJECTIONS, INTRAVENOUS; MICE; MICE, INBRED ICR; MOLECULAR IMAGING; ORGANOTECHNETIUM COMPOUNDS; PROTEIN BINDING; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS; TECHNETIUM; TISSUE DISTRIBUTION;

EID: 80052197163     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules16086165     Document Type: Article

References (23)

1. King, M.A.; Weber, D.A.; Casarett, G.W.; Burgener, F.A.; Corriveau, O. A study of irradiated bone. Part II: Changes in Tc-99m pyrophosphate bone imaging. J. Nucl. Med. 1980, 21, 22-30. (Pubitemid 10161380)
2. Valdez, V.A.; Jacobstein, J.G. Decreased bone uptake of technetium-99m polyphosphate inthalassemia major. J. Nucl. Med. 1980, 21, 47-49. (Pubitemid 10161383)
3. 99mTc-labeled phosphate and phosphonate agents for skeletal imaging. J. Nucl. Med. 1976, 6, 19-31.
4. Subramanian, G.; McAfee, J.G.; Blair, R.J. Technetium-99m-methylene diphosphonate-a superior agent for skeletal imaging: Comparison with other technetium complexes. J. Nucl. Med. 1975, 16, 744-755.
5. Fogelman, I.; Pearson, D.W.; Bessent, R.G.; Tofe, A.J.; Francis, M.D. A comparison of skeletal uptakes of three diphosphonates by whole-body. J. Nucl. Med. 1981, 22, 880-883. (Pubitemid 11020545)
6. Cole, T.J.; Balseiro, J.; Lippman, H.R. Technetium-99m-methylene diphosphonate (MDP) uptake in a sympathetic effusion: An index of malignancy and a review of the literature. J. Nucl. Med. 1991, 32, 325-327.
7. 99mTc-MDP scintigraphic findings in children with leukemia: Value of early and delayed whole-body imaging. J. Nucl. Med. 2001, 42, 878-883. (Pubitemid 32537434)
8. Love, C.; Din, A.S.; Tomas, M.B.; Kalapparambath, T.P.; Palestro, C.J. Radionuclide bone imaging: An illustrative review. Radiographics 2003, 23, 341-358. (Pubitemid 37431266)
9. 99mTc-chelate conjugated bisphosphonate with high affinity for bone as a bone scintigraphic agent. J. Nucl. Med. 2006, 47, 2042-2047. (Pubitemid 47544992)
10. Smith, M.R. Osteoclast targeted therapy for prostate cancer: Bisphosphonates and beyond. Urol. Oncol.: Semin. Orig. Investig. 2008, 26, 420-425. (Pubitemid 351885378)
11. m-ZL. Nucl. Tech. (in Chinese) 2006, 29, 438-441.
12. m-EIDP. Nucl. Tech. (in Chinese) 2008, 31, 698-701.
13. 99Tcm-PIDP as bone imaging agent. Nucl. Sci. Tech. 2009, 20, 302-306.
14. 99mTc-EMIDP. Appl. Radiat Isot. 2010, 9, 1616-1622.
15. 99mTc-i-PIDP: A new bone imaging agent. Appl. Radiat Isot. 2011, 69, 1169-1175.
16. Lin, J.G.; Qiu, L.; Cheng, W.; Luo, S.N.; Ye, W.Z. Preparation and in vivo biological investigations on a novel radioligand for bone scanning: Technetium-99m-labeled zoledronic acid derivative. Nuel. Med. Biol. 2011, 38, 619-629.
17. 99mTc-EC with aminomethylene diphosphonate in the search for a bone tracer with fast clearance from soft Tissue. Bioconjug. Chem. 2002, 13, 16-22. (Pubitemid 34119630)
18. Valko, K. Application of high-performance liquid chromatography based measurements of lipophilicity to model biological distribution. J. Chromatogr. A 2004, 1037, 299-310. (Pubitemid 38591346)
19. 99mTc(Sn)HMDP. Nucl. Med. Biol. 1988, 5, 479-487.
20. Vallner, J.J. Binding of drugs by albumin and plasma protein. J. Pharm. Sci. 1977, 66, 447-465.
21. Major, P.; Lortholary, A.; Hon, J.; Abdi, E.; Mills, G.; Menssen, H.D.; Yunus, F.; Bell, R.; Body, J.; Quebe-Fehling, E.; Seaman, J. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 2001, 19, 558-567. (Pubitemid 32112871)
22. Berenson, J.R. Recommendations for zoledronic acid treatment of patients with bone metastases. Oncologist 2005, 10, 52-62. (Pubitemid 40171251)
23. Widler, L.; Jaeggi, K.A.; Glatt, M.; Müller, K.; Bachmann, R.; Bisping, M.; Born, A.R.; Cortesi, R.; Guiglia, G.; Jeker, H.; et al. Highly potent geminal bisphosphonates. From pamidronate disodium (aredia) to zoledronic acid (zometa). J. Med. Chem. 2002, 45, 3721-3738. (Pubitemid 34863233)